Clinical trials: SCID

Peanut Allergy

ARTEMIS Peanut Allergy In Children

• Completed
• Age: 4 to 17 years
• Phase 3
• Pill or oral medicine
• Results posted

The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.

Trial name

ARTEMIS (NCT03201003)

Testing

AR101 powder provided in capsules & sachets

Where

18 sites in France, Germany and 5 more

Volunteers

175 people

Sponsor

Aimmune Therapeutics, Inc.